News
Vantia Therapeutics appoints new CEO
9 June 2010
Vantia Therapeutics today announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO). more»
VA111913 structure revealed
26 March 2010
Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913, at the ACS National Meeting. more»

Vantia Therapeutics Pipeline - Business Development
Vantia Therapeutics' strategy is to develop its proprietary drug candidates to Phase II proof-of-concept and then commercialise through partnerships.
For more information on the product opportunities in development, please contact:
-
Andy Crockett
VP Business Development
t +44 23 8076 3400
bus.dev@vantia.com
